At the conclusion of oral opposition proceedings on September 11, 2014, the European Patent Office (“EPO”) maintained Shire’s European patent covering VYVANSE® (marketed as ELVANSE® in Europe). The Opposition Division of the EPO found that EP 1644019, as amended, met the requirements of the European Patent Convention, including novelty and inventive step. The opposition was initiated by Johnson Matthey, Generics U.K. (trading as Mylan), and Hexal (an affiliate of Sandoz).

To view the decision, please click here.